T-cell prolymphocytic leukemia surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Surgery== | ==Surgery== | ||
Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission. | [[Autologous]] and [[allogeneic]] [[Stem cell transplant|stem cell transplants]] is the mainstay of [[therapy]] for [[Patient|patients]] who achieve [[Remission (medicine)|remission]]. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 14:03, 4 April 2019
T-cell prolymphocytic leukemia Microchapters |
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
T-cell prolymphocytic leukemia surgery On the Web |
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia surgery |
Risk calculators and risk factors for T-cell prolymphocytic leukemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3]
Surgery
Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission.